Elizabeth Garrett-Mayer to Research Design
This is a "connection" page, showing publications Elizabeth Garrett-Mayer has written about Research Design.
Connection Strength
0.244
-
Approaches to phase 1 clinical trial design focused on safety, efficiency, and selected patient populations: a report from the clinical trial design task force of the national cancer institute investigational drug steering committee. Clin Cancer Res. 2010 Mar 15; 16(6):1726-36.
Score: 0.062
-
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements. Clin Pharmacol Ther. 2008 Jul; 84(1):111-8.
Score: 0.053
-
The continual reassessment method for dose-finding studies: a tutorial. Clin Trials. 2006; 3(1):57-71.
Score: 0.046
-
A likelihood-based approach for computing the operating characteristics of the 3+3 phase I clinical trial design with extensions to other A+B designs. Clin Trials. 2015 Feb; 12(1):24-33.
Score: 0.021
-
Dose-finding clinical trial design for ordinal toxicity grades using the continuation ratio model: an extension of the continual reassessment method. Clin Trials. 2012 Jun; 9(3):303-13.
Score: 0.018
-
Proportional odds model for dose-finding clinical trial designs with ordinal toxicity grading. Stat Med. 2011 Jul 30; 30(17):2070-80.
Score: 0.017
-
Is there coercion or undue inducement to participate in health research in developing countries? An example from Rakai, Uganda. J Clin Ethics. 2009; 20(2):141-9.
Score: 0.014
-
A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst. 2007 Mar 07; 99(5):376-85.
Score: 0.013